Influence of hyperhomocysteinemia on the cellular redox state--impact on homocysteine-induced endothelial dysfunction

Norbert Weiss1, Stanley J Heydrick, Otilia Postea

  • 1Medizinische Poliklinik--Innenstadt, Klinikum der Universität München, Munich, Germany. Norbert.Weiss@med.uni-muenchen.de

Insights

High homocysteine levels contribute to atherosclerosis by increasing oxidative stress, which damages blood vessels. Antioxidant treatments can reverse this damage, suggesting oxidative stress is a key factor in homocysteine

Area of Science:

  • Vascular Biology
  • Oxidative Stress Research
  • Cardiovascular Disease Pathophysiology

Background:

  • Hyperhomocysteinemia is a known risk factor for atherosclerosis.
  • Oxidative stress is increasingly recognized as a contributor to homocysteine's vascular damage.

Purpose of the Study:

  • To investigate the role of oxidative stress in homocysteine-induced vascular dysfunction.
  • To explore the potential of antioxidant interventions in mitigating these effects.

Main Methods:

  • Examined homocysteine's impact on superoxide generation and antioxidant enzyme function.
  • Assessed the effects of superoxide scavenging (using superoxide dismutase or Tiron) and antioxidant enhancement (glutathione, glutathione peroxidase) on endothelial function in animal models and isolated tissues.

Main Results:

  • Elevated homocysteine increases superoxide generation, partly via nitric oxide synthase and homocysteine oxidation.
  • Homocysteine alters cellular antioxidant enzyme function, amplifying superoxide levels.
  • Increased superoxide inactivates nitric oxide, causing endothelial dysfunction.
  • Superoxide scavenging and antioxidant boosting reversed homocysteine-induced endothelial dysfunction.

Conclusions:

  • The adverse vascular effects of hyperhomocysteinemia are significantly mediated by oxidative stress.
  • Oxidative inactivation of nitric oxide by superoxide is a key mechanism in homocysteine-induced endothelial dysfunction.
  • Antioxidant strategies show promise for treating vascular complications associated with hyperhomocysteinemia.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...